文献速递呼吸道感染肺栓塞与肺血管病呼吸危重症与机械通气

组织型纤溶酶原激活剂治疗SARS-CoV-2 COVID-19呼吸衰竭的研究:一项多中心、快速适应性、实用性随机对照先锋试验

Study of Alteplase for Respiratory Failure in SARS-CoV-2 COVID-19: A Vanguard Multicenter, Rapidly Adaptive, Pragmatic, Randomized Controlled Trial.
PubMed 文献 · Chest · 2021-09-27

该研究纳入COVID-19诱导的呼吸衰竭成人患者,随机分为对照组和tPA推注组或tPA滴注组,评估tPA改善肺功能的安全性和有效性。结果显示tPA推注联合肝素安全,推注组PaO2/FiO2在6至168小时显著高于基线,但48小时主要终点组间差异未达统计学显著。

要点

  • tPA推注联合肝素在重症COVID-19呼吸衰竭中未发生严重出血事件。
  • tPA推注组PaO2/FiO2在6至168小时显著高于基线,对照组无显著改善。
  • 48小时PaO2/FiO2变化百分比、复合结局、无呼吸机天数和死亡率组间差异未达统计学显著。

核心结论

  • tPA推注联合肝素在重症COVID-19呼吸衰竭中是安全的。
  • 鉴于氧合改善以及无呼吸机天数和死亡率的有希望观察,有必要进行3期研究。

研究设计与样本

  • 多中心、快速适应性、实用性随机对照试验,2020年5月14日至2021年3月3日随机入组COVID-19诱导呼吸衰竭的成人患者。
  • 1期(n=36)为对照组(标准治疗) vs tPA推注组(50 mg tPA静脉推注后7天肝素,目标aPTT 60-80秒)。
  • 2期(n=14)为对照组 vs tPA滴注组(50 mg tPA静脉推注后tPA 2 mg/h加肝素500单位/h持续24小时,随后肝素维持aPTT 60-80秒7天)。
  • 排除既往4.5小时内未进行神经系统检查或脑横断面成像以排除卒中和出血转化可能的患者。
  • 主要结局为随机化后48小时PaO2/FiO2较基线的改善。

主要发现

  • 共50例患者随机:1期对照组17例、tPA推注组19例;2期对照组8例、tPA滴注组6例。
  • 未发生严重出血事件。
  • tPA推注组PaO2/FiO2在随机化后6至168小时显著高于基线(P < .017);对照组无显著改善。
  • tPA推注组与对照组比较:48小时PaO2/FiO2变化百分比(16.9% [IQR -8.3%至36.8%] vs 29.8% [IQR 4.5%-88.7%];P = .11)、复合结局(11.8% vs 47.4%;P = .03)、无呼吸机天数(0.0 [IQR 0.0-9.0] vs 12.0 [IQR 0.0-19.0];P = .11)、院内死亡率(41.2% vs 21.1%;P = .19)均未达到统计学显著差异。
  • 接受tPA滴注的患者未获益。

关键数值与推荐

  • tPA推注方案:50 mg tPA静脉推注后7天肝素,目标aPTT 60-80秒。
  • tPA滴注方案:50 mg tPA静脉推注后tPA 2 mg/h加肝素500单位/h持续24小时,随后肝素维持aPTT 60-80秒7天。
  • 主要结局:随机化后48小时PaO2/FiO2较基线改善。
  • 复合结局:48小时PaO2/FiO2改善> 50%或PaO2/FiO2 ≥ 200。
  • tPA推注组PaO2/FiO2在6至168小时显著高于基线(P < .017)。

临床怎么用

  • tPA推注联合肝素可用于重症COVID-19呼吸衰竭患者且未发生严重出血事件。
  • tPA推注可改善氧合,但需注意主要终点组间差异未达统计学显著。
  • tPA滴注未显示获益,不推荐使用。

局限性

  • 样本量小(共50例),各期组例数少。
  • 主要终点48小时PaO2/FiO2变化百分比组间差异未达统计学显著(P = .11)。
  • 复合结局、无呼吸机天数和死亡率组间差异未达统计学显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pulmonary vascular microthrombi are a proposed mechanism of COVID-19 respiratory failure. We hypothesized that early administration of tissue plasminogen activator (tPA) followed by therapeutic heparin would improve pulmonary function in these patients. RESEARCH QUESTION: Does tPA improve pulmonary function in severe COVID-19 respiratory failure, and is it safe? STUDY DESIGN AND METHODS: Adults with COVID-19-induced respiratory failure were randomized from May14, 2020 through March 3, 2021, in two phases. Phase 1 (n = 36) comprised a control group (standard-of-care treatment) vs a tPA bolus (50-mg tPA IV bolus followed by 7 days of heparin; goal activated partial thromboplastin time [aPTT], 60-80 s) group. Phase 2 (n = 14) comprised a control group vs a tPA drip (50-mg tPA IV bolus, followed by tPA drip 2 mg/h plus heparin 500 units/h over 24 h, then heparin to maintain aPTT of 60-80 s for 7 days) group. Patients were excluded from enrollment if they had not undergone a neurologic examination or cross-sectional brain imaging within the previous 4.5 h to rule out stroke and potential for hemorrhagic conversion. The primary outcome was Pao2 to Fio2 ratio improvement from baseline at 48 h after randomization. Secondary outcomes included Pao2 to Fio2 ratio improvement of > 50% or Pao2 to Fio2 ratio of ≥ 200 at 48 h (composite outcome), ventilator-free days (VFD), and mortality. RESULTS: Fifty patients were randomized: 17 in the control group and 19 in the tPA bolus group in phase 1 and eight in the control group and six in the tPA drip group in phase 2. No severe bleeding events occurred. In the tPA bolus group, the Pao2 to Fio2 ratio values were significantly (P < .017) higher than baseline at 6 through 168 h after randomization; the control group showed no significant improvements. Among patients receiving a tPA bolus, the percent change of Pao2 to Fio2 ratio at 48 h (16.9% control [interquartile range (IQR), -8.3% to 36.8%] vs 29.8% tPA bolus [IQR, 4.5%-88.7%]; P = .11), the composite outcome (11.8% vs 47.4%; P = .03), VFD (0.0 [IQR, 0.0-9.0] vs 12.0 [IQR, 0.0-19.0]; P = .11), and in-hospital mortality (41.2% vs 21.1%; P = .19) did not reach statistically significant differences when compared with those of control participants. The patients who received a tPA drip did not experience benefit. INTERPRETATION: The combination of tPA bolus plus heparin is safe in severe COVID-19 respiratory failure. A phase 3 study is warranted given the improvements in oxygenation and promising observations in VFD and mortality. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT04357730; URL: www. CLINICALTRIALS: gov.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Barrett CD, Moore HB, Moore EE, et al. Study of Alteplase for Respiratory Failure in SARS-CoV-2 COVID-19: A Vanguard Multicenter, Rapidly Adaptive, Pragmatic, Randomized Controlled Trial. Chest. 2021. PMID: 34592318. doi:10.1016/j.chest.2021.09.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。